<DOC>
	<DOCNO>NCT01891240</DOCNO>
	<brief_summary>The overall objective IMPROvED project develop sensitive , specific , high-throughput economically viable early pregnancy screen test preeclampsia . This involve multicentre , phase IIa clinical predictive study assess refine novel innovative prototype test base emerge metabolomic proteomic technology develop SMEs ( small medium size enterprise ) within consortium . The study ) recruit 5000 first-time pregnant woman ; ii ) establish high calibre biobank , augment accurate clinical metadata ; iii ) determine whether prototype predictive assay algorithms translate clinical environment ; iv ) ass potential synergy combine metabolomic proteomic approach v ) progress regulatory approval development select test clinical arena .</brief_summary>
	<brief_title>IMproved PRegnancy Outcome Early Detection</brief_title>
	<detailed_description>Sample size calculation consider extensively give complexity study ; single simple solution . For purpose sample size estimation overall study , use binary outcome associate measure sensitivity likelihood ratio determinant value test . Although predictive algorithm produce continuous risk score , use categorical outcome fit final binary decision process ( treat treat ) base risk score . Based low estimate prevalence pre-eclampsia 3 % test sensitivity 93 % test specificity 97 % , 90 % certain true specificity patient population le 95 % , sample size 4,800 participant require . Thus , allow patient dropout , study population 5,000 woman need .</detailed_description>
	<mesh_term>Pre-Eclampsia</mesh_term>
	<mesh_term>Eclampsia</mesh_term>
	<mesh_term>Pregnancy Complications</mesh_term>
	<criteria>Nulliparous . Singleton pregnancy , 9+0 16+6 week ' gestation . Signed informed consent . Unsure last menstrual period ( LMP ) unwilling ultrasonography screening ( USS ) ≤ 20 week . ≥ 3 miscarriage . ≥3 termination pregnancy . Known suspected major fetal anomaly/abnormal karyotype . Essential hypertension treat prepregnancy . Moderatesevere hypertension booking ( BP &gt; 160/100 mmHg ) . Diabetes mellitus . Renal disease . Systemic lupus erythematosus . Antiphospholipid syndrome . Sickle cell disease . HIV positive . Hepatitis B C positive . Major uterine anomaly . Cervical suture situ . Knife cone biopsy . Longterm steroid . Treatment lowdose aspirin . Treatment heparin/LMW heparin . Lack informed consent . After recruitment , woman find outside state gestation limit IMPROvED 1st visit 9 week 0 day 13 week 6 day retain study willing take part second third visit otherwise eligible . There one prespecified criterion discontinuation participant . If woman recruit IMPROvED study later identify pregnancy exclusion criterion , i.e. , ≥ 3 miscarriage , ≥ 3 TOPS , use lowdose aspirin time recruitment , shall exclude . However , woman diagnose pregnancy recruitment exclusion criterion , e.g. , diseases renal disease , antiphospholipid syndrome , etc . shall retain within study . Women recruit later discontinue study count towards recruitment target centre . Accordingly , dropout must replace .</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Diagnostic</keyword>
	<keyword>Pre-eclampsia</keyword>
	<keyword>Pregnancy outcome</keyword>
	<keyword>Mass screening</keyword>
	<keyword>Diagnostic Techniques Procedures</keyword>
</DOC>